News | January 09, 2024
Lupin launches second edition of Aptivate Champion Run for Kids
Lupin Life encourages children from Mumbai, Thane, and Navi Mumbai to participate in Aptivate Champion Run
Lupin Life encourages children from Mumbai, Thane, and Navi Mumbai to participate in Aptivate Champion Run
TALZENNA is the first and only PARP inhibitor approved in combination with standard of care XTANDI for mCRPC patients in the European Union
Collaboration provides AstraZeneca with exclusive rights to Omniose’s proprietary bioconjugation platform to explore potential vaccines for a broad range of bacterial pathogens
The deal includes upfront payments, milestone payments and ongoing royalties
Comprehensive clinical development programs being initiated for each investigational candidate
The congress aims at emphasizing on the most recent trends, advancements in the field of Obstetrics & Gynaecology
Liraglutide belongs to the class of glucagon like peptide 1 receptor agonist (GLP?1 RA) drugs
Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes
Vyleesi is the first and only as-needed treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)
AMI to become part of Enpro’s Sealing Technologies Segment
Subscribe To Our Newsletter & Stay Updated
